TD Cowen analyst Ritu Baral downgraded Spero Therapeutics (SPRO) to Hold from Buy without a price target The firm cites a lack of clarity on catalyst timing following discontinuation of the SPR720 Phase 2 program for the downgrade. TD now sees a lack of clarity on meaningful catalyst flow for the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRO: